Updated information on COVID-19 and Flu: Restricted visitation is now in effect
Category
Cancer
Sub Category
Melanoma
Study Name
EA6134: A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma
Principal Investigator
Gordan Srkalovic, MD, PhD
Study Information
https://www.clinicaltrials.gov/ct2/show/NCT02224781?term=EA6134&rank=1
Contact for Questions
Nurse - Tracy 517-364-2835

Site view: at a glance